Last Price
48.70
Today's Change
-1.10 (2.20%)
Day's Change
48.53 - 50.03
Trading Volume
10,345,417
Market Cap
98 Billion
Shares Outstanding
2 Billion
Avg Volume
14,981,275
Avg Price (50 Days)
45.68
Avg Price (200 Days)
47.74
PE Ratio
-14.98
EPS
-3.25
Earnings Announcement
31-Oct-2024
Previous Close
49.80
Open
49.79
Day's Range
48.53 - 50.03
Year Range
39.35 - 61.43
Trading Volume
10,973,715
1 Day Change
-2.21%
5 Day Change
-2.03%
1 Month Change
4.73%
3 Month Change
17.41%
6 Month Change
-8.60%
Ytd Change
-7.70%
1 Year Change
-18.79%
3 Year Change
-25.30%
5 Year Change
1.27%
10 Year Change
-4.86%
Max Change
2299.01%
No result.
Sector: Healthcare - Healthcare
Industry: Drug Manufacturers—General
Description:
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.